In adults with MI and LVEF ≥40%, β-blocker therapy reduced a composite adverse outcome at a median 3.5 y

Research output: Contribution to journalArticlepeer-review

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Original languageEnglish
Pages (from-to)JC135
JournalAnnals of Internal Medicine
Volume178
Issue number12
DOIs
StatePublished - Dec 1 2025

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'In adults with MI and LVEF ≥40%, β-blocker therapy reduced a composite adverse outcome at a median 3.5 y'. Together they form a unique fingerprint.

Cite this